



RepliCel™

Using Cells for Healing


OTCQB: REPCF | TSXV: RP | FRA:P6P2

COMPANY PROFILE Q1 2017

A Revolution in Sports Medicine and Aesthetics.

We are a regenerative medicine company with innovative cell therapy technology providing unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.

Three applications, two biologics,
one game-changing delivery platform



RCI-02 PATENTED DERMAL INJECTION DEVICE

The RCI-02 dermal injector is designed to deliver cells, dermal fillers, drug and biologics.

- Digital controls program for depth, volume, rate of dispersion
- Provides exact repeatable dispersion across 3 dimensions
- Removes human variability
- Built-in Peltier element reduces need for anesthetics
- Near-term commercial launch

Poised for growth and momentum



Potential to Revolutionize Sports Medicine and Aesthetics

This innovative cell therapy technology has the potential to revolutionize two large consumer-pay markets where few solutions exist.

The Only Regenerative Medicine Company Using Hair Follicle Cell Therapy

We are the only Company using cells derived from hair follicles to potentially heal damaged skin and tendon tissue—offering hope for people with conditions beyond repair.

Multiple Assets Addressing Conditions With Unmet Need

Multi-product portfolio diversifies risk over several programs in two different markets.

Near-Term Commercialization And Revenue

Patented injection device could generate sales and revenues as early as 2018 in Europe, and then in the U.S.

Exceptional Timing Ahead Of Important Catalysts

Three biologic products are in Phase I and II human clinical trials with safety data reading out in Q1'2017; first could reach the market in 2018.

Management Is Commercially-Focused And Strategic

Aggressively pursuing licensing and co-development deals over the next 24 months.

Capital Structure (as at Feb 2, 2017)

Current market cap. (approx.)	~\$25M
Total money raised through equity to-date	~\$22M
Total revenue to-date (including initial Shiseido licensing payment)	\$3.8M
Current Monthly Burn Rate	~\$180,000
Shares Issued and Outstanding (Basic/FD) (post-consolidation completed in Aug 2016)	15.6M

Board and Management Team

David Hall
Chairman

Geoff MacKay, BSc
Director

Peter Lewis, CA
Director

Dr. John Challis, PhD
Director

Hugh Rogers, BSc, LLB
Director

R. Lee Buckler, B. Ed, LLB
President, CEO & Director

Dr. Rolf Hoffman, MD
Chief Medical Officer

Dr. Kevin McElwee, PhD
Chief Scientific Officer

Tom Kordyback, CA
Chief Financial Officer

Darrell Panich, MSc, PMP, CPM
Clinical Consultant

RepliCel Life Sciences

Suite 900, 570 Granville Street
Vancouver, BC V6C 3P1
604-248-8730

www.replicel.com